Skip to content
Bored Studies
RecruitingAccepts healthy volunteersMentions an overnight / inpatient stay

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)

Bettina Mittendorfer · with National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06571474

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
60
US sites recruiting
1
Study start
August 1, 2024
Record last updated
August 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.

Both groups will have

  • screening visit
  • imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans)
  • Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies

Conditions: Obesity; Non-Alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • age: ≥18 but ≤70 years
  • not pregnant or breastfeeding
  • weight stable and sedentary before enrollment
  • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group)
  • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
  • participants must fulfil all of the following group-specific inclusion criteria below:

Lean group

  • Body mass index (BMI) ≥18.5 but \<25.0 kg/m2
  • Intrahepatic triglyceride (IHTG) content \<5%
  • fasting blood glucose concentration: \<100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
  • Hemoglobin A1C (HbA1c) \<5.7 %

Metabolically normal obesity (MNO) group:

  • BMI ≥30.0 but \<45.0 kg/m2
  • IHTG content \<5%
  • fasting blood glucose concentration: \<100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
  • HbA1c \<5.7 %

Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:

  • BMI ≥30.0 but \<45.0 kg/m2
  • IHTG content >7.5%
  • fasting blood glucose concentration: ≥100 but \<126 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \<200 mg/dl
  • HbA1c: ≥5.7 but \<6.4 %

MAO-type 2 diabetes group:

  • BMI ≥30.0 but \<45.0 kg/m2
  • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes

Exclusion Criteria

  • Individuals that do not meet all inclusion Criterion

Recruiting US locations

  • University of Missouri School of Medicine

    Columbia, MO 65212

    Site contact: Bettina Mittendorfer · 573-882-9377 · b.mittendorfer@missouri.edu

Study contacts (from the official record)

  • Heather McHatton · 573-882-7619 · heathermchatton@health.missouri.edu
  • Aman Pritish Aher · amanpritishaher@missouri.edu
All weight loss studies in Missouri →
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) (NCT06571474) | Bored Studies